Takanori Tomotsune

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Teruo Jojima, Takanori Tomotsune, Toshie Iijima et al. · Diabetology & Metabolic Syndrome · 2016 · 197 citations · Full text

Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice

Teruo Jojima, Kohsuke Uchida, Kazumi Akimoto et al. · Atherosclerosis · 2017 · 101 citations

Inflammation, Glp-1 Receptor Agonist, Apoe Deficient Mice +11

Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy

Seiichi Tanaka, Kunihiro Suzuki, Chie Aoki et al. · Diabetes Technology & Therapeutics · 2014 · 29 citations · Full text

Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells

Toshie Iijima, Kanako Kato, Teruo Jojima et al. · Diabetes Research and Clinical Practice · 2017 · 19 citations

Diabetes Management, Autoimmune Disease, Fulminant Type 1 +9